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BACKGROUND: We investigated, in the panel of 60 human tumour cell lines of the National Cancer Institute (NCI-60), whether the
R72P polymorphism of TP53 and the T309G polymorphism of MDM2 were associated to the in vitro cytotoxicity of anticancer
agents, extracted from the NCI database. For validation, the same study was performed independently on a second panel of tumour
cell lines, JFCR-45.
METHODS: Both SNPs were identified in cell DNA using PCR-RFLP techniques confirmed by direct sequencing and by pyrosequencing.
For the analysis of the results, the mutational status of p53 was taken into account.
RESULTS: In the NCI-60 panel, the TP53 rare-allele frequency was 32% and the MDM2 rare-allele frequency 39%. The MDM2 alleles
were distributed according to Hardy–Weinberg equilibrium whereas this was only found, for the TP53 alleles, in p53 non-mutated
cell lines. Comparable results were obtained in the JFCR-45 validation set. The TP53 SNP had low impact on anticancer drug
cytotoxicity in either panel. In contrast, the MDM2 gene polymorphism had a major impact on anticancer drug cytotoxicity, essentially
in p53 non-mutated cell lines. Presence of the rare allele was associated to significantly higher MDM2 protein expression and to
increased sensitivity to DNA-interfering drugs. In the JFCR-45 panel, a similar effect of the MDM2 gene polymorphism was observed,
but was less dependent on the p53 mutational status.
CONCLUSIONS: We hypothesised that cell lines harbouring the MDM2 G allele presented a lower availability of p53 for DNA repair,
translating into higher sensitivity to DNA-damaging agents.
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Numerous genetic factors influence the cytotoxicity of anticancer
drugs and can explain, at least in part, the variability in individual
responses to chemotherapy. Using in vitro models of the Centre
d’E ´tude du Polymorphisme Humain, the group of ME Dolan at
Chicago has evidenced the genetic components of drug response in
non-tumour cells (Huang et al, 2007a,b, 2008). We and others have
used the NCI-60 model to show the relationships between the
presence of a given polymorphic variation and the in vitro
cytotoxicity of many anticancer drugs (Yarosh et al, 2005;
Le Morvan et al, 2006; Moisan et al, 2006; Nief et al, 2007). The
NCI-60 model consists of a panel of 60 human tumour cell lines
of various origins which has served for the primary screening of
thousands of potential anticancer drugs (Monks et al, 1991). The
free availability of the databases elaborated by the Developmental
Therapeutic Program (DTP) of the National Cancer Institute (NCI)
allows to establish genotype/phenotype associations on a large
number of drugs without performing drug cytotoxicity assays. The
fact that the cell lines are of tumour origin adds a special advantage
when the polymorphisms studied concern genes encoding drug
targets or proteins involved in DNA repair, because the activity of
such proteins in the tumour is expected to be important in drug
cytotoxicity. On the contrary, polymorphisms in genes responsible
for drug metabolism or transport would be more interesting to
study in germ-line cells rather than in tumour cells, because they
are expected to have a function in drug toxicity in the clinical
setting.
The p53–MDM2 pathway is especially important for drug
activity. Activation of p53 following exposure to cell stress leads to
cell-cycle arrest and/or apoptosis and to DNA repair (Vogelstein
et al, 2000). The loss of p53 function by oncogenic mutations
provides cancer cells an opportunity to exacerbate their genetic
instability and, hence, their tumourigenic and invasive properties
(Lee et al, 1994). p53 is especially involved in response to DNA-
damaging anticancer agents and TP53 mutations lead to the loss of
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sapoptosis induced by these agents (Lowe et al, 1994). Many studies
have tried to relate the occurrence of tumour TP53 mutations to
drug activity with conflicting results (for reviews see Brown and
Wouters, 1999; Gasco and Crook, 2003; Cimoli et al, 2004). For
instance, when drug cytotoxicity is evaluated as inhibiting growth
inhibition, cells bearing a TP53 mutation are significantly less
sensitive to a wide range of drugs than cells with wild-type TP53;
however, when drug cytotoxic activity is evaluated as cloning
efficiency inhibition, no difference appears between cells with
mutated and wild-type TP53 (Brown and Wouters, 1999). In the
clinics, the question has not yet received definitive answers;
it appears, however, that a loss of p53 function is frequently
associated with resistance to treatment in several malignancies
(Gasco and Crook, 2003). However, in a recent study on basal-like
breast cancers treated by neo-adjuvant chemotherapy using
an alkylating agent (cyclophosphamide), all tumours harbouring
a mutated p53 presented a complete pathological response to
treatment (Bertheau et al, 2007).
The TP53 gene bears a polymorphism in exon 4, resulting in
the replacement of an arginine residue by proline (R72P). This
polymorphism has been found with an allele frequency of about
25% in Caucasian populations, giving rise to about 6% variant
homozygous subjects. It has been shown that the R common
form of p53 is able to induce apoptosis markedly better than does
the P variant form in cell lines containing inducible wild-type
p53 (Dumont et al, 2003). In in vitro models, the response to
anticancer drugs such as cisplatin and doxorubicin appears higher
for the R allele than for the P allele (Yarosh et al, 2005). The p53
polymorphic status has been determined in the NCI panel and has
been associated with a decrease in drug cytotoxicity of alkylating
agents in heterozygous cell lines (Sullivan et al, 2004) as compared
to both variant and common homozygous cell lines. In the clinical
setting, it has been shown in a series of advanced head and
neck cancers that the polymorphism in wild-type p53 influences
the clinical outcome of the treatment, with significantly shorter
survival in homozygous patients with the P variant allele
(Bergamaschi et al, 2003). In contrast, opposite results were
obtained for patients with tumours harbouring a mutated form of
p53: patients with the P allele had higher response rates than those
expressing the R allele. Another example comes from the study of
the response of patients with breast cancer to adjuvant tamoxifen;
the p53 R72P polymorphism appears as a predictor of tamoxifen
response, and the authors suggest that patients with breast cancer
lacking the P allele might be candidates for other therapies
(Wegman et al, 2006).
An important regulator of p53 activity is MDM2. Exploration of
the p53 stress response pathway led to the discovery of a functional
polymorphism in the MDM2 intronic promoter (T309G, allele
frequency around 30%) (Bond et al, 2004). The variant allele has
been shown to have increased affinity to the MDM2 transcriptional
activator Sp1, resulting in higher levels of MDM2 protein and
subsequent attenuation of the p53 pathway. This polymorphism is
associated with accelerated tumour formation in both hereditary
and sporadic cancers (for a review see Bond and Levine, 2007) and
a meta-analysis recently concluded that variant homozygote G/G
was associated with a significantly increased risk of all types of
tumours (Hu et al, 2007). Its possible effect on anticancer drug
response remains to be established, but a recent study comparing
cell lines with different MDM2 genotypes revealed a lower
sensitivity of the G/G homozygous variant to topoisomerase
II-interfering drugs (Nayak et al, 2007).
MATERIALS AND METHODS
We used in this study two independent sets of human tumour cell
lines for which in vitro sensitivity to a panel of anticancer drugs
had been established, the NCI-60 collection (Monks et al, 1991)
and the JFCR-45 collection (Nakatsu et al, 2005). DNA extracts
from 59 of the 60 NCI cell lines of the panel were kindly provided
by Dr S Holbeck, Cancer Therapeutic Branch, NCI, Bethesda, MD,
USA. One cell line, MDA-N, is no longer available in the panel.
DNA extracts were prepared from 42 cell lines of the JFCR-45
collection.
Polymerase chain reactions (PCRs) were performed on genomic
DNA using appropriate primers (see below). Polymorphisms were
detected in the NCI-60 panel by restriction fragment length
polymorphism (RFLP) analysis on PCR products, using appro-
priate restriction enzymes. Electrophoresis of the PCR products
was performed before and after digestion on 10% polyacrylamide
gels. The presence of a variation was translated into the occurrence
or the disappearance of a restriction site on the PCR product,
leading to two shorter products. This technique allowed the
unambiguous discrimination between homozygous cell lines with
the common-allele, homozygous cell lines with the rare-allele and
heterozygous cell lines, for both polymorphisms studied (G466C of
TP53, rs1042522 and T309G of MDM2, rs2279744). Sequencing was
performed on randomly chosen PCR products from the various
genotypes of the variations studied. Concordance with RFLP was
obtained in 100% of the cases.
We used the following primers for the G466C variation
(R72P) of TP53: sense, 50-TCCCCCTTGCCGTCCCAA-30; antisense,
50-CGTGCAAGTCACAGACTT-30. The PCR products were then
digested by BstUI, which specifically cleaves the common G allele,
and subjected to 10% polyacrylamide gel electrophoresis.
For the T309G variation of MDM2, we used the following
primers: sense, 50-GAGTTCAGGGTAAAGGTCAC-30; antisense,
50-TCAAGAGGAAAAGCTGAGTC-30. The PCR products were
digested by MspAI, which specifically cleaves the variant G allele,
and subjected to 10% polyacrylamide gel electrophoresis.
To confirm these results by a second independent technique, we
also identified both polymorphisms by pyrosequencing. The DNA
extracts of the JFCR-45 collection were exclusively studied by
pyrosequencing. Direct sequencing of the PCR fragments without
any further purification was performed on the Pyrosequencer
PyroMark ID system (Biotage, Uppsala, Sweden) according to the
instructions of the manufacturer. In that case, the primers we used
were as follows: for TP53: sense, 50 dR-Biotin-CACTGAAGACCC
AGGTCCAGAT 30; antisense, 50-CCGGTGTAGGAGCTGCTGG-30;
MDM2: sense, 50-CAGGGTAAAGGTCACGGG-30; antisense,
50 dR-Biotin-AGGCACCTGCGATCATCC 30.
After identification of the genotypes of each cell line, the 50%
growth-inhibiting concentrations (GIC50) of 136 core drugs
vis-a `-vis the 59 NCI-60 cell lines, expressed as –log10(GIC50),
were extracted from the DTP database (http://dtp.nci.nih.gov).
Similarly, the growth-inhibitory concentrations (GI50s) of 53
agents against the cell lines of the JFCR-45 collection were
extracted from the original publication (Nakatsu et al, 2005).
Drugs were grouped as a function of their known mechanism of
action into eight categories (for details see Scherf et al, 2000):
alkylating or platinating agents acting on N
7 of guanine; other
alkylating agents, acting on N
2 and O
6 of guanine; antimetabolites;
antifolates; topoisomerase I inhibitors; topoisomerase II inhibitors;
spindle poisons, subdivided into vinca-alkaloid-type and taxane-
type mechanisms of action. With each cell line collection
independently, it was possible to directly compare the mean
GIC50 values of each drug in the various genotypes, and it was also
possible to use a paired Student’s t-test to analyse the data related
to drug classes.
The mutational status of TP53 of the NCI-60 collection was
extracted from the NCI database, which integrates the data
obtained by O’Connor et al (1997) and those obtained in the
more recent study of Ikediobi et al (2006). There are some discre-
pancies between the two data sets and we chose the second one
(Ikediobi et al, 2006) that results from genomic DNA resequen-
cing. The JFCR cell lines had been also characterised for p53
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smutational status by Frontier Science Co., Ltd (Ishikari, Hokkaido,
Japan) according to the method described by Flaman et al (1995).
The expression of MDM2 in the NCI-60 collection was extracted
from the DTP database. Numerous different data sets are available,
1 obtained by mRNA dot blots and 20 by Affymetrix microarray
analysis. Unfortunately, there were no available data obtained by
RT–PCR, which is considered as the reference method to quantify
mRNA products. We chose in the database the most recent data set
(September 2008 release), which indeed presented good correla-
tions with most other data sets (Affymetrix U133A microarrays
generated by Dr E Moler, ref. GC232415). MDM2 expression was
also obtained on Affymetrix microarrays in the JFCR-45 collection
as described by Kanno et al (2006). Five MDM2 probe sets were
available on these arrays; based on expression intensity, we chose
the probe 217373_x_at for comparisons of MDM2 expression
according to TP53 and MDM2 genotypes.
The w
2-test was used for comparing the distribution of the cell
lines among genotypes. Pearson coefficients of correlation were
computed for comparing continuous variables (GIC50 and gene
expression data). To study the pharmacological parameters as a
function of the genotype, we analysed the variances of drug GIC50s
values or MDM2 expression for each genotype and calculated the
significance of the differences in mean values, using a general
linear model taking into account the unbalanced size of the groups.
The Bonferroni correction was applied to take into account the
number of tests performed. The two cell line collections were
studied independently, the NCI-60 collection as a training test and
the JFCR-45 collection as a validation test, to decrease the
probability of generating falsely positive observations.
RESULTS
Identification of TP53 and MDM2 genotypes
Figure 1 shows some representative electrophoretic profiles of PCR
products before and after digestion with the appropriate restric-
tion enzymes. Table 1 lists the 59 NCI cell lines and their genotypic
status for the polymorphisms considered, as well as the p53
mutational status extracted from the NCI database. Some
discrepancies between our results and those published earlier
(Yarosh et al, 2005) were resolved by sequencing the complete
exon 4, which confirmed the RFLP results. The results obtained by
pyrosequencing were identical to those obtained by RFLP for all 59
cell lines. No special trend appeared concerning the presence or
absence of a given genotype as a function of the tissue of origin of
the cells. Concerning the TP53 variation (Table 2), there were 35
cell lines with the homozygous common-allele genotype G/G, 10
heterozygous cell lines G/C and 14 with the homozygous rare-allele
genotype C/C, giving a rare-allele frequency of 32% if all cell lines
were diploid. This distribution was significantly different from the
expected Hardy–Weinberg distribution (Po0.001). When con-
sidering separately the cell lines with wild-type and mutated p53, it
appeared that the frequency of the rare C allele was significantly
higher (P¼0.026) in cell lines with mutated p53 (38.4%) than in
cell lines with wild-type p53 (15.6%). Especially, all the cell lines
with the homozygous C/C genotype were found among the p53-
mutated cell lines. In addition, the heterozygous cell lines
harboured less frequently a p53 mutation than homozygous cell
lines. Concerning the MDM2 variation (Table 2), there were 25 cell
lines with the homozygous common-allele genotype T/T, 23
heterozygous cell lines T/G and 11 with the homozygous rare-
allele genotype G/G, giving a rare-allele frequency of 38% and no
significant distortion from a Hardy–Weinberg distribution. The
same distribution was exhibited by cell lines with wild-type and
mutated p53.
In the JFCR-45 panel, the rare TP53 allele frequency was 25%
and the proportion of heterozygous cell lines was also significantly
lower than expected from Hardy–Weinberg distribution (Table 2).
However, due to the lower number of cell lines, it was not possible
to detect a significant difference between the rare-allele frequency
in the p53 wild-type and the p53 mutated cell lines. As in the NCI
panel, the heterozygous cell lines harboured less frequently a p53
mutation than homozygous cell lines. The rare MDM2 allele
frequency was 46% and the genotype distribution not significantly
different from expected by the Hardy–Weinberg distribution
(Table 2).
Associations between genotypes and gene expression and
drug cytotoxicity
We looked for associations between the presence of a given
genotype of TP53 and the cytotoxicity of individual drugs of the
NCI database. The statistical analysis took into account the fact
that multiple comparisons were made. When the whole NCI-60
panel was considered, several significant associations could be
found between the TP53 variation and drug activity for some of
the 136 drugs, such as fluorouracil, methotrexate, busulfan and
cisplatin. The heterozygous cell lines appeared slightly more
sensitive to these drugs than the rare-allele homozygous cell lines.
Pooling the drugs as a function of their mechanism of action
revealed that these differences were significant for alkylating
agents (GIC50 ratio¼1.4, P¼7 10
 6, Figure 2) and antifolates
(GIC50 ratio¼1.7, P¼2 10
 5, data not shown). However, these
differences were not observed when the mutational status of p53 in
the cell line panel was taken into account. Indeed, and independent
of the polymorphisms of TP53, one can notice a highly significant
MDM2 TP53
165 pb
119 pb
ND D  ND  D  ND D  ND D  ND  D      MK
279 pb
MK   D    ND    D   ND    D   ND    D   ND
46 pb
160 pb
119 pb
HT VAR VAR WT VAR
HT HT VAR WT
Figure 1 Representative electrophoretic patterns of PCR products before (ND) and after (D) digestion for the identification of TP53 and MDM2
polymorphisms. The deduced genotypes are indicated below each couple of lanes.
MDM2 polymorphism and anticancer drug sensitivity
N Faur et al
352
British Journal of Cancer (2009) 101(2), 350–356 & 2009 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
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lines having a p53 mutation had a significantly lower sensitivity to
most drugs than cell lines having no p53 mutation. The mean
GIC50 ratio reaches 2 for alkylating agents (P¼8 10
 8, Figure 2)
and 3 for antifolates (P¼4 10
 4, data not shown).
No consistent association between MDM2 genotype and cell
sensitivity to the 136 core drugs could be evidenced when they
were sought in the whole NCI-60 panel. When the drugs were
pooled as a function of their mechanism of action, a significant
difference could be evidenced for alkylating agents: the cell lines
containing a G allele were slightly more sensitive to this class of
agents than the common homozygous cell lines (GIC50 ratio¼1.3,
P¼4 10
 7, Figure 3). However, when the cell lines were analysed
separately as a function of the presence or absence of p53
mutations, it appeared that the polymorphism in the MDM2 genes
was associated with significant differences in drug cytotoxicity
only in cell lines with wild-type functional p53, and not in cell lines
harbouring a p53 mutation. In these cell lines, the presence of the
rare G allele at position 309 of the MDM2 gene was associated to an
important and significant increase in the cytotoxicity of numerous
individual DNA-interfering drugs (alkylating agents, inhibitors of
topoisomerases I and II) (Table 3). When the drugs were pooled as
a function of their mechanism of action, it appeared that the mean
Table 1 Polymorphisms of the TP53 and MDM2 genes found in the
NCI-60 panel
Tumor type Cell line
Mutational
p53 status
SNP
TP53
SNP
MDM2
Leukaemia CCRF-CEM Mut G/C T/G
HL-60 Mut C/C T/G
K-562 Mut C/C T/G
MOLT-4 Mut G/G T/T
RPMI-8226 Mut C/C T/T
SR WT G/C G/G
Lung cancer A549/ATCC WT G/G T/T
EKVX Mut G/C T/G
HOP-62 Mut G/G T/T
HOP-92 Mut C/C T/T
NCI-H226 WT G/G T/G
NCI-H23 Mut C/C T/T
NCI-H322M Mut G/G G/G
NCI-H460 WT G/G T/G
NCI-H522 Mut G/G T/T
Colon cancer COLO-205 Mut G/G T/T
HCC-2998 Mut G/C T/G
HCT-116 WT G/G T/T
HCT-15 Mut G/G T/G
HT29 Mut C/C T/G
KM12 Mut G/C G/G
SW-620 Mut G/G T/G
Central nervous
system
SF-268 Mut G/G T/G
SF-295 Mut G/G T/G
SF-539 Mut G/G G/G
SNB-19 Mut G/G T/T
SNB-75 Mut C/C T/T
U251 Mut G/G T/T
Melanoma LOXIMVI WT G/G T/G
MALME-3M WT G/G T/G
M14 Mut G/G G/G
SK-MEL-2 Mut C/C T/T
SK-MEL-28 Mut C/C T/T
SK-MEL-5 WT G/G T/T
UACC-257 WT C/G T/G
UACC-62 WT G/G G/G
Ovarian cancer IGROV1 Mut G/G T/T
OVCAR-3 Mut G/G T/T
OVCAR-4 Mut G/G T/G
OVCAR-5 WT G/G T/T
OVCAR-8 Mut G/G T/T
SK-OV-3 Mut C/C T/T
Renal cancer 786-0 Mut G/C T/G
A498 WT G/G T/T
ACHN WT G/G T/G
CAKI-1 WT G/C T/G
RXF-393 Mut C/C G/G
SN-12C Mut G/G G/G
TK-10 Mut G/G T/G
UO-31 WT G/C T/T
Prostate cancer PC-3 Mut C/C T/T
DU-145 Mut G/G T/G
Breast cancer MCF-7 WT G/C T/G
NCI/ADR-RES Mut G/G T/T
MDA-MB-231 Mut G/G T/G
HS578T Mut G/G G/G
MDA-MB-435 Mut G/G G/G
BT-549 Mut C/C T/T
T-47D Mut C/C G/G
Table 2 Distribution of TP53 and MDM2 genotypes between the
NCI-60 and the JFCR-45 panels
Polymorphism Genotype
Whole
panel
Wild-type
p53
Mutated
p53
NCI-60 panel
TP53 R72P G/G 35 11 24
G/C 10 5 5
C/C 14 0 14
MDM2 T309G T/T 25 6 19
T/G 23 8 15
G/G 11 2 9
JFCR-45 panel
TP53 R72P G/G 28 3 25
G/C 7 7 0
C/C 7 3 4
MDM2 T309G T/T 15 4 11
T/G 15 6 9
G/G 12 3 9
p53 R72P
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Figure 2 Schematic representation of the association between the
TP53 genotype of the cell lines of the NCI-60 panel and the cytotoxicity
of alkylating agents. The GIC50s of the drugs of this class towards the
60 cell lines, expressed as  log10(GIC50), were normalised to zero,
the cytotoxicities higher than the mean with a positive sign and the
cytotoxicities lower than the mean a negative sign. Data are means±s.e.m.
Cells were either taken all together (left) or as a function of the p53 status
(middle and right). White columns, common homozygous cell lines; grey
columns, heterozygous cell lines; black columns, variant homozygous cell
lines.
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lines with a G allele reached 2.5 for alkylating agents (P¼3.7 
10
 10, Figure 3), 2.2 for topoisomerase I inhibitors (P¼5.1 10
 7,
data not shown) and 2.4 for topoisomerase II inhibitors (P¼3.8 
10
 7, data not shown). Due to the fact that only two cell lines had a
homozygous G/G genotype in the p53 wild-type subset, it was not
possible to study them separately from heterozygous cell lines, but
it should be noticed that these two cell lines presented the lowest
GIC50 values for most DNA-interfering drugs.
We also looked for associations between MDM2 expression and
polymorphism in the NCI-60 panel. As expected, there was a
significantly lower MDM2 expression in cell lines having a mutated
p53 than in cell lines having no p53 mutation (expression
ratio¼1.57, P¼1.5 10
 5). There was no association between
MDM2 polymorphism and MDM2 expression in the whole cell line
panel; however, when the cell lines with and without a p53
mutation were considered separately, it appeared that, among the
cell lines with no p53 mutation, those harbouring at least one G
allele at position 309 of MDM2 had a significantly increased MDM2
expression (expression ratio¼1.6, P¼1.6 10
 5) (Table 3 and
Figure 4, right). This was not observed in p53-mutated cell lines
(Figure 4, left). The association between MDM2 expression and
anticancer drug cytotoxicity was only weak, despite the fact that
MDM2 expression was higher in p53 wild-type cells, which are
themselves more sensitive to DNA-damaging drugs. Especially,
camptothecin and doxorubicin cytotoxicities were significantly
correlated to MDM2 expression in p53 wild-type cells.
In the JFCR-45 panel, we observed, as in the NCI-60 panel, a
significant relationship between the mutational status of p53 and
the cytotoxicity of most anticancer drugs belonging to the classes
of alkylating agents, topoisomerase inhibitors and antimetabolites.
When the cytotoxic drug panel was considered as a whole, the
mean ratio of GIC50 values between wild-type and p53-mutated cell
lines was 1.35 (P¼6.0 10
 3). However, the TP53 polymorphism
was not associated to differences in the cytotoxicity of any
anticancer drug or drug class. The polymorphism of the MDM2
gene was in contrast associated, as in the NCI-60 panel, to major
differences in drug sensitivity, the cell lines harbouring the variant
MDM2 G allele being more chemosensitive than those harbouring
only the common T allele; this was detected mainly in cell lines
MDM2 T309G
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Figure 3 Schematic representation of the association between the
MDM2 genotypes of the cell lines of the NCI-60 panel and the cytotoxicity
of alkylating agents. Same legend as Figure 2.
Table 3 MDM2 expression and GIC50 values of three representative drugs against the NCI-60 and JFCR-45 cell lines as a function of the MDM2 genotype
and of the p53 mutational status
p53 status MDM2 genotype Melphalan GIC50 (lM) Doxorubicin GIC50 (lM) Camptothecin GIC50 (lM) MDM2 expression
NCI-60 panel
Mutated TT 31.6 0.140 0.044 23.8
TG+GG 28.6 0.171 0.055 21.3
Wild type TT 46.7 0.159 0.031 25.4
TG+GG 13.3
a 0.045
a 0.016
a 40.9
a
JFCR-45 panel
Mutated TT 38.3 0.198 0.055 1.17
TG+GG 25.7 0.099 0.014
a 1.27
Wild type TT 21.1 0.137 0.38 1.54
TG+GG 16.3 0.055
a 0.070
a 2.92
aA significant difference according to the MDM2 genotype.
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Figure 4 MDM2 gene expression as a function of the genotype of the
cell lines of the NCI-60 panel. MDM2 expression was extracted from the
DTP database (http://dtp.nci.nih.gov); the data set chosen originates from
experiments on Affymetrix U133A microarrays realised by Dr E Moler, ref.
GC232415. Cell lines with mutated p53 are on the left of the panel, and
cell lines with wild-type p53 are on the right. White columns, common
homozygous cell lines; grey columns, heterozygous cell lines; black columns,
variant homozygous cell lines.
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swith wild-type p53 but also in cell lines where a mutation of p53
was detected, although to a lesser extent (Table 3). In p53 wild-type
cell lines of the JFCR-45 panel, the mean GIC50 ratio of cytotoxic
agents in cell lines with no G allele vs cell lines with a G allele
reached 7.0 (P¼2 10
 10), whereas it was only 2.4 in p53-mutated
cell lines. As in the NCI-60 panel, the expression of MDM2 in the
JFCR-45 panel was higher in p53 wild-type cell lines than in p53-
mutated cell lines (expression ratio¼2.0, P¼2 10
 4) and, in
p53 wild-type cell lines, MDM2 expression was higher in cell
lines harbouring at least one G allele (expression ratio¼1.9)
(Table 3) but this did not reach significance (P¼0.11) because
of the small number of cell lines with common homozygous
MDM2 genotype.
DISCUSSION
The higher sensitivity of p53 wild-type cells, as compared to
p53 mutated cells, to most anticancer agents (excluding
spindle poisons), is a very general feature when cytotoxicity is
evaluated by growth inhibition (Brown and Wouters, 1999). It
was already observed by O’Connor et al (1997) in the NCI-60 panel
and will not be further discussed here. The R72P polymorphism
of p53 in the NCI panel had already been shown to be
important in the cytotoxicity of several anticancer agents (Yarosh
et al, 2005), especially those whose mechanism of action involves
p53-mediated apoptosis. Yarosh et al (2005) had observed that the
heterozygous cell lines were significantly more sensitive to
alkylating agents than both common-allele and rare-allele homo-
zygous cell lines. We found that this difference was significant only
between heterozygous and rare-allele homozygous lines, but not
between heterozygous and common-allele homozygous cell lines.
The higher drug sensitivity of heterozygous cell lines in the NCI
panel may be in fact related to the higher proportion of this
genotype among the p53 non-mutated subset of the NCI-60 panel
(31% vs 11% in the p53 mutated subset) and would not be a
characteristic of the genotype. Indeed, there was no significant
difference in drug sensitivity as a function of the TP53
polymorphism in the JFCR-45 panel, which confirms that the
difference seen in the NCI panel should be a bias due to the
distribution of the genotypes. However, this last observation is
interesting per se: the higher proportion of heterozygotes among
wild-type p53 tumours in both panels has never been mentioned
before. It could be simply related to the loss of heterozygosity at
the TP53 locus during evolution of p53 mutated, genetically
unstable, tumours. It can also be hypothesised that the TP53
heterozygous genotype may protect against the occurrence of p53
mutations. Researching both the p53 mutational status and the
TP53 polymorphism in clinical samples would be warranted to
confirm this hypothesis.
The MDM2 gene is one of the numerous transcriptional targets
of p53 and the MDM2 protein induces the proteasomal degrada-
tion of p53. Its polymorphism present in the 50 untranslated region
has been consistently associated with an increased transcription
rate and a subsequent attenuation of p53, leading to an activation
of tumour formation and growth (Bond and Levine, 2007). The
most striking observation made in our study is that, in both cell
line panels studied independently, this polymorphism may be
important in the cytotoxicity of anticancer agents against tumour
cell lines, and that, in the NCI-60 panel, this effect is limited to the
tumours having no p53 mutation. The cell lines harbouring at least
one variant G allele of MDM2 in this subset appeared 2- to 5-fold
more sensitive to most DNA-interfering agents than the homo-
zygous wild-type cell lines. This was not evidenced in cell lines
with a mutated p53 and, therefore, should be related to the
existence of a functional p53-dependent pathway. However, the
higher drug sensitivity of the G allele-containing cell lines was
observed in both p53 mutated and non-mutated cell lines of the
JFCR-45 panel. This could be because not all p53 mutations exert
the same effect on p53 function: it had been shown, for instance,
that the 173H and the 273H mutations were able to induce
apoptosis whereas most other mutations were not (Sta ¨hler and
Roemer, 1998). A difference in the distribution of p53 mutations
in the two panels could explain why the MDM2 gene polymor-
phism is associated to chemosensitivity in the p53-mutated
subset of the JFCR panel and not on the corresponding subset
of the NCI-60 panel. In addition, the presence of the rare G allele
in both cell line panels was associated with an increase in MDM2
gene expression. This result was expected because the G allele
of MDM2 has increased affinity to the MDM2 transcriptional
activator Sp1.
The observation that the rare G allele of MDM2 is associated
with increased drug cytotoxicity in these two models was
unexpected, because the reduction of p53 availability in the
variant cell lines would be suspected to lead to a decrease in drug-
induced apoptosis and cell death. In addition, it was shown in
recent studies that this polymorphism was associated with a worse
outcome of cancer disease (Gryshchenko et al, 2008). However, no
clinical study has evaluated separately the overall prognosis of the
disease and the predictive function of the polymorphism on
response to treatment. The degree of malignancy of a tumour cell
is related, at least in part, to its rate of proliferation, as is its
sensitivity to antiproliferative agents. In experimental models as in
the clinical setting, the most rapidly growing tumours are also the
most sensitive to anticancer drugs. It has been shown that, for
instance, in a series of 431 patients with breast cancer the most
aggressive tumours (SBR grade III) responded better to neo-
adjuvant chemotherapy than the less aggressive ones (SBR grade I)
(Po10
 6) (Amat et al, 2002). Consequently, the overall prognosis
of a cancer is not simply related to its responsiveness to
chemotherapy. In the NCI-60 panel, the cell doubling times have
been evaluated and are significantly correlated with chemosensi-
tivity; however, no relationship could be evidenced between the
polymorphisms studied and the cell doubling times, showing that
the association between MDM2 polymorphism and drug cytotoxi-
city was independent from the rate of cell-cycle progression.
At the cellular level, it should be borne in mind that p53 is
involved in many functions in the cell: it is not only in charge of
inducing apoptosis in response to DNA damage (especially drug-
induced DNA damage), but also of inducing DNA repair following
drug-induced damage. One can hypothesise that the second
function of p53 would be preponderant in the culture conditions
of the cell line panels. As a consequence, the higher MDM2 activity
associated with the variant genotype would be responsible for a
decrease in p53-mediated DNA repair, which would explain in turn
why the cytotoxicity of DNA-interfering agents is higher in cell
lines harbouring the variant G allele of MDM2. One can also
hypothesise that the variant allele brings an additional alkylation
site of for agents whose mechanism of action involves covalent
binding to a guanine, which is the case of most alkylators; in these
conditions, the cytotoxicity of these agents would be dependent
upon the number of G alleles in the promoter of the MDM2 gene.
However, the higher drug sensitivity of T/G and G/G cell lines in
comparison to T/T cell lines also applies to topoisomerase I-
targeting and topoisomerase II-targeting drugs, rendering this
mechanism unlikely.
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